Type 2 diabetes mellitus is a complex and heterogeneous disorder. The pathogenesis involves multiple mechanisms which contribute to hyperglycaemia, most notably impaired insulin secretion by pancreatic \u3b2-cells, reduced glucose uptake by skeletal muscle and adipose tissue (peripheral insulin resistance) and increased hepatic glucose production. Although basal insulin secretion may remain within the normal range, the meal-time insulin response is blunted or delayed in patients with type 2 diabetes mellitus, which causes post-prandial hypoglycaemia.
New treatments for patients with type 2 diabetes mellitus.Wolffenbuttel BH, Graal MB.Department of E...
BACKGROUND: The more rapid onset of action and the shorter half-life of repaglinide may reduce the p...
To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incre...
Type 2 diabetes mellitus is a complex and heterogeneous disorder. The pathogenesis involves multiple...
Dept. of Endocrinology and Metabolism, University Hospital Maastricht, The Netherlands. bwo@sint.azm...
As the prevalence of type 2 diabetes continues to rise, new drug therapies will need to be explored ...
OBJECTIVE — Repaglinide, a novel antidiabetic agent that has a rapid onset and short du-ration of ac...
OBJECTIVE - To examine the dose-related pharmacodynamics and pharmacokinetics of a single preprandia...
This article reviews the clinical evidence and pharmacological rationale for repaglinide, a prandial...
To compare the effect of Repaglinide vs Glimepiride on glucose- and meal-induced insulin secretion a...
Repaglinide is a short-acting insulin secretagogue used for the reduction in postprandial glucose le...
The combination of oral antidiabeticdrugs and bedtime insulin is cur-rently regarded as the first-li...
OBJECTIVE—To assess the effects of incremental doses of repaglinide on postprandial insulin and gl...
WOS: 000243353400012PubMed ID: 17211567In this study, we investigated the effects of combining prepr...
The role of postprandial hyperglycemia (PPHG) in diabetes mellitus is being increasingly recognized....
New treatments for patients with type 2 diabetes mellitus.Wolffenbuttel BH, Graal MB.Department of E...
BACKGROUND: The more rapid onset of action and the shorter half-life of repaglinide may reduce the p...
To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incre...
Type 2 diabetes mellitus is a complex and heterogeneous disorder. The pathogenesis involves multiple...
Dept. of Endocrinology and Metabolism, University Hospital Maastricht, The Netherlands. bwo@sint.azm...
As the prevalence of type 2 diabetes continues to rise, new drug therapies will need to be explored ...
OBJECTIVE — Repaglinide, a novel antidiabetic agent that has a rapid onset and short du-ration of ac...
OBJECTIVE - To examine the dose-related pharmacodynamics and pharmacokinetics of a single preprandia...
This article reviews the clinical evidence and pharmacological rationale for repaglinide, a prandial...
To compare the effect of Repaglinide vs Glimepiride on glucose- and meal-induced insulin secretion a...
Repaglinide is a short-acting insulin secretagogue used for the reduction in postprandial glucose le...
The combination of oral antidiabeticdrugs and bedtime insulin is cur-rently regarded as the first-li...
OBJECTIVE—To assess the effects of incremental doses of repaglinide on postprandial insulin and gl...
WOS: 000243353400012PubMed ID: 17211567In this study, we investigated the effects of combining prepr...
The role of postprandial hyperglycemia (PPHG) in diabetes mellitus is being increasingly recognized....
New treatments for patients with type 2 diabetes mellitus.Wolffenbuttel BH, Graal MB.Department of E...
BACKGROUND: The more rapid onset of action and the shorter half-life of repaglinide may reduce the p...
To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incre...